Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Introduced
Moved
Reached a final decision
Introduced 2026-04-30
Derived from the official record below.
Officially: “Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026” Read the full text
Health
What it does
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research an
Summary by the Congressional Research Service, from the official record. Plain-language AI rewrite coming. Not legal advice.
Where it is
Introduced · 2026-04-30
In the Senate.
Passed the Senate · 2026-08-04
House floor vote · next
Official documents
The numbers
29%
of bills that passed one chamber became law in the 118th Congress, 2023 to 2024 (n=939)
16
sponsors, out of 51 needed to pass
Who is lobbying on this
I AM ALSvia I AM ALS
1 filingMUSCULAR DYSTROPHY ASSOCIATION, INC.via MUSCULAR DYSTROPHY ASSOCIATION, INC.
1 filingTHE ALS ASSOCIATIONvia THE ALS ASSOCIATION
1 filingFrom 3 filings in federal lobbying disclosures (LDA), via lda.gov, naming this bill (2026). Filings are self-reported by lobbying firms and show who is paid to influence this bill. They do not say which side, or whether it worked.
Every fact on this page links to its source, starting with the official bill record. Last action: Held at the desk. (2026-08-10).